Lucie Hamel, Ph.D.
Affiliations: | 2004 | Université de Montréal, Montréal, Canada |
Area:
Oncology, Molecular BiologyGoogle:
"Lucie Hamel"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Simone Chevalier | grad student | 2004 | Université de Montréal | |
| (Role de l'endogline et de la proteine kinase c -tak1 dans le cancer de la prostate.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Derderian S, Benidir T, Scarlata E, et al. (2023) Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression. The Journal of Pathology. Clinical Research |
| Ebrahimizadeh W, Guérard KP, Rouzbeh S, et al. (2023) A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients. British Journal of Cancer |
| Derderian S, Vesval Q, Wissing MD, et al. (2022) Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer. Clinical and Translational Science |
| Bramhecha YM, Guérard KP, Audet-Walsh É, et al. (2022) Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients. Oncogene |
| Aprikian S, Luz M, Brimo F, et al. (2019) Improving ultrasound-based prostate volume estimation. Bmc Urology. 19: 68 |
| Bramhecha YM, Rouzbeh S, Guérard KP, et al. (2018) The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc |
| Bramhecha YM, Guérard KL, Rouzbeh S, et al. (2017) Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome After Surgical Intervention. Molecular Cancer Research : McR |
| Audet-Walsh É, Dufour CR, Yee T, et al. (2017) Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes & Development |
| Rochette A, Boufaied N, Scarlata E, et al. (2017) Asporin is a stromally expressed marker associated with prostate cancer progression. British Journal of Cancer |
| Altaylouni T, Zouanat F, Scarlata E, et al. (2017) PD65-12 THE ANDROGEN RECEPTOR BECOMES A NOVEL PREDICTIVE BIOMARKER OF PROSTATE CANCER PROGRESSION WHEN POST TRANSLATIONALLY ACTIVATED BY THE FER KINASE ON TYROSINE 223 Journal of Urology. 197 |